Wordt geladen...
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
BACKGROUND: Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death th...
Bewaard in:
| Gepubliceerd in: | Breast Cancer Res |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6343247/ https://ncbi.nlm.nih.gov/pubmed/30670061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-1092-x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|